Trenbolone
Trenbolone is an anabolic steroid whose current US authorization is for cattle implants. Human interviews and surveys report aggression, mood changes and heart and liver concerns. Human studies have not established a controlled estimate of muscle gain.
Anabolic-androgenic steroid
- Current US use is veterinary
- Human safety concerns
What is trenbolone, and what is it approved for?
Trenbolone is an anabolic-androgenic steroid. The cited current US authorization is for acetate implants in cattle, not a human medicine.
Historical Parabolan, acetate implants and underground products labeled enanthate are different formulations. Evidence about one does not establish another’s identity, release rate or safety.
US regulation · cattle implants
Veterinary regulation
21 CFR 522.2476.
The regulation authorizes specified trenbolone acetate ear implants for steers and heifers, with feed-efficiency and weight-gain indications. It is not a human authorization.
Read the original sourceParabolan · historical record
Archived product record
BIAM historical French product record.
The archived catalog reference identifies Parabolan as trenbolone hexahydrobenzylcarbonate, a different ester from acetate and enanthate.
Read the original sourceHow much muscle or fat loss has been measured in people?
Available human studies did not measure muscle or fat changes against a control group.
The rat study measured androgen-sensitive muscle, bone and fat over 29 days. International user interviews describe perceived physical enhancement, but lacked placebo groups and objective comparisons of muscle gain.
Trenbolone enanthate · rat muscle study
Animal experiment
American journal of physiology. Endocrinology and metabolism. PMID 21266670.
A 29-day experiment in intact and castrated male rats found increased androgen-sensitive muscle mass and partial protection against bone loss and visceral-fat accumulation. Higher exposures also increased prostate mass.
Muscle, fat, bone and prostate changes were measured in rats. No human benefit or safety estimate was measured.
Read the original sourceInternational interviews · benefits and adverse experiences
Qualitative interview study
Drug and alcohol review. PMID 39433468.
Thirty consumers described sought physical and psychological effects alongside emotional volatility and intrusive thoughts.
Reported benefits are not controlled efficacy findings. Participants’ harm-reduction practices were not tested for effectiveness.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
Does the old human experiment change that answer?
WHO’s account of the historical human experiment describes nitrogen retention over 14 days, not an athletic-performance or body-composition trial. The account does not report sample size or control allocation.
WHO · historical human observations
Official toxicology review of historical study
WHO/JECFA, Food Additives Series 23; citing Krüskemper et al., 1967.
WHO describes a 14-day intramuscular acetate experiment in male and female volunteers. It records nitrogen retention and, at the higher exposure, menstrual disturbances in some women and reduced urinary 17-ketosteroids.
The account does not give sample size or control allocation. Nitrogen balance is not measured muscle gain, and the food-residue assessment is not a human dosing recommendation.
Read the original sourceIs the hard, dry look proven?
Available controlled evidence does not establish an appearance or water-balance effect. Visual changes reported by users cannot establish dehydration, a predictable fat-loss rate or safety.
International interviews · benefits and adverse experiences
Qualitative interview study
Drug and alcohol review. PMID 39433468.
Thirty consumers described sought physical and psychological effects alongside emotional volatility and intrusive thoughts.
Reported benefits are not controlled efficacy findings. Participants’ harm-reduction practices were not tested for effectiveness.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
What do human studies say about mental side effects?
Interviews and surveys repeatedly report mood and behavioral problems associated with trenbolone. They establish a concern, but cannot prove that every reported effect was caused by trenbolone.
The 16-user interview study described aggression and impulsivity problems. A separate 30-consumer study described emotional volatility and intrusive thoughts. A 282-man survey linked reported amount with higher verbal-aggression scores after limited adjustment.
User interviews · aggression and impulsivity
Qualitative interview study
Drug and alcohol review. PMID 36992616.
Interviews involving 16 anabolic-steroid users described aggression, violent behavior and difficulty regulating impulses in connection with trenbolone.
Interviews describe experiences. They cannot establish incidence or isolate the effect of one drug.
Read the original sourceInternational interviews · benefits and adverse experiences
Qualitative interview study
Drug and alcohol review. PMID 39433468.
Thirty consumers described sought physical and psychological effects alongside emotional volatility and intrusive thoughts.
Reported benefits are not controlled efficacy findings. Participants’ harm-reduction practices were not tested for effectiveness.
Read the original source282-man survey · verbal aggression
Cross-sectional survey
The International journal on drug policy. PMID 39486244.
Among 282 men using anabolic steroids, reported trenbolone amount was associated with higher verbal-aggression scores after adjustment for age and BMI.
Self-selected participants, self-reported exposure and residual confounding prevent a causal interpretation.
Read the original sourceHow strong is the larger international comparison?
In the Global Drug Survey, 237 trenbolone users reported more mood, irritability and depressive concerns than 909 other steroid users. Exposure and outcomes were self-reported; the comparison cannot rule out different combinations, use patterns or pre-existing differences.
Global Drug Survey · reported health concerns
Cross-sectional survey
Drug and alcohol review. PMID 42037159.
Among 1,146 male anabolic-steroid users, the 237 reporting past-year trenbolone use reported more mood, cardiovascular and hepatic concerns than the 909 reporting other steroids without trenbolone.
The outcomes are self-reported concerns, not independently confirmed organ diagnoses. Other substances and selection can confound the comparison.
Read the original sourceWhat is known about heart, liver and other physical risks?
The larger survey found more cardiovascular and hepatic concerns among trenbolone users. It did not measure a medically confirmed event rate.
Anabolic-steroid class risks include blood-pressure and cholesterol problems, cardiovascular injury, liver injury and androgenic effects. Trenbolone-specific rates of these harms have not been established.
Global Drug Survey · reported health concerns
Cross-sectional survey
Drug and alcohol review. PMID 42037159.
Among 1,146 male anabolic-steroid users, the 237 reporting past-year trenbolone use reported more mood, cardiovascular and hepatic concerns than the 909 reporting other steroids without trenbolone.
The outcomes are self-reported concerns, not independently confirmed organ diagnoses. Other substances and selection can confound the comparison.
Read the original sourceFDA · steroid-product risks
Regulatory safety review
US FDA, 2017.
Anabolic-steroid products have been associated with serious liver and cardiovascular injury, mood changes, adverse lipids, androgenic effects and reproductive suppression.
This describes class-level concerns. It does not estimate a specific compound’s risk.
Read the original sourceWhat about night sweats, insomnia or “tren cough”?
User accounts raise these questions, but available evidence does not establish a reliable incidence, a proven explanation for each symptom or a validated way to prevent them. Sudden breathing difficulty or chest pain should not be dismissed as a routine drug effect.
International interviews · benefits and adverse experiences
Qualitative interview study
Drug and alcohol review. PMID 39433468.
Thirty consumers described sought physical and psychological effects alongside emotional volatility and intrusive thoughts.
Reported benefits are not controlled efficacy findings. Participants’ harm-reduction practices were not tested for effectiveness.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
Have serious acute reactions been reported in people?
A case report described recurrent acute pancreatitis in a 24-year-old man after trenbolone-acetate reuse, after the authors reported excluding other common and uncommon causes. Rechallenge strengthens the signal, but one case cannot establish incidence or rule out every product and co-exposure uncertainty.
Trenbolone acetate · recurrent pancreatitis case
Case report
Clinical toxicology. PMID 30101635.
A 24-year-old man had recurrent acute pancreatitis temporally associated with trenbolone-acetate use and recurrence after reuse. The authors reported an extensive workup excluding other common and uncommon causes.
Recurrence after reuse strengthens attribution within this report. A single case cannot estimate frequency or verify every product and co-exposure.
Read the original sourceCan trenbolone affect reproductive function?
Yes, there are human hormonal observations and substantial animal evidence that raise concern. Neither gives a reliable individual recovery timeline.
WHO’s summary of the short human experiment records menstrual disturbances in some women. Animal toxicology describes reproductive and endocrine effects. Anabolic-steroid class evidence also includes suppression of sperm production.
WHO · historical human observations
Official toxicology review of historical study
WHO/JECFA, Food Additives Series 23; citing Krüskemper et al., 1967.
WHO describes a 14-day intramuscular acetate experiment in male and female volunteers. It records nitrogen retention and, at the higher exposure, menstrual disturbances in some women and reduced urinary 17-ketosteroids.
The account does not give sample size or control allocation. Nitrogen balance is not measured muscle gain, and the food-residue assessment is not a human dosing recommendation.
Read the original sourceFDA · steroid-product risks
Regulatory safety review
US FDA, 2017.
Anabolic-steroid products have been associated with serious liver and cardiovascular injury, mood changes, adverse lipids, androgenic effects and reproductive suppression.
This describes class-level concerns. It does not estimate a specific compound’s risk.
Read the original sourceThe veterinary food-residue assessment uses very different exposures and aims. Its acceptable residue intake cannot be converted into a safe bodybuilding dose.
WHO · historical human observations
Official toxicology review of historical study
WHO/JECFA, Food Additives Series 23; citing Krüskemper et al., 1967.
WHO describes a 14-day intramuscular acetate experiment in male and female volunteers. It records nitrogen retention and, at the higher exposure, menstrual disturbances in some women and reduced urinary 17-ketosteroids.
The account does not give sample size or control allocation. Nitrogen balance is not measured muscle gain, and the food-residue assessment is not a human dosing recommendation.
Read the original sourceWhy do animal anabolic results not settle human safety?
An androgen can affect muscle and other organs at the same time. The rat experiment found muscle effects alongside dose-dependent prostate changes.
The study’s search for tissue selectivity does not establish clinical selectivity in people. It cannot identify a human dose that keeps the sought effects while avoiding cardiovascular, reproductive or psychiatric harm.
Trenbolone enanthate · rat muscle study
Animal experiment
American journal of physiology. Endocrinology and metabolism. PMID 21266670.
A 29-day experiment in intact and castrated male rats found increased androgen-sensitive muscle mass and partial protection against bone loss and visceral-fat accumulation. Higher exposures also increased prostate mass.
Muscle, fat, bone and prostate changes were measured in rats. No human benefit or safety estimate was measured.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
Can human urine studies establish an injection half-life?
No. The two modern human studies measured metabolites after administration of free trenbolone. They did not measure blood clearance of acetate or enanthate injections.
A cattle kinetic measurement cannot establish a human injection half-life. Depot release, metabolism and urine detection describe different processes.
Human metabolism · 1991 experiment
Single-person human metabolism study
Journal of chromatography. PMID 1874853.
One human subject received orally administered radiolabeled free trenbolone. Researchers measured urinary recovery and metabolites over 72 hours.
Oral free-parent metabolism does not establish the plasma half-life of an injected ester.
Read the original sourceHuman metabolism · 2020 experiment
Single-person human metabolism study
Frontiers in chemistry. PMID 32509736.
One healthy man received labeled trenbolone for an analytical study. Investigators collected urine and identified additional metabolites.
The experiment was designed for doping analysis, not muscle, mood, organ-safety or efficacy outcomes.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
What can blood tests tell you?
Blood tests can identify some adverse changes during steroid use. They cannot verify a vial’s ingredients or rule out every risk.
The cited sources do not establish a modern controlled human benefit-risk estimate. The cited ClinicalTrials.gov records contain no exact-term trial, while historical pharmacology and observational reports remain part of the evidence.
FDA · steroid-product risks
Regulatory safety review
US FDA, 2017.
Anabolic-steroid products have been associated with serious liver and cardiovascular injury, mood changes, adverse lipids, androgenic effects and reproductive suppression.
This describes class-level concerns. It does not estimate a specific compound’s risk.
Read the original sourceClinicalTrials.gov · no exact-name trenbolone study
Trial registrations
ClinicalTrials.gov.
ClinicalTrials.gov lists no exact-name trenbolone study. Historical exposure studies and contemporary surveys remain separate human evidence.
The registry result does not establish the absence of all human research. Historical exposure studies and contemporary surveys exist.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
Studies and sources
US regulation · cattle implants
Veterinary regulation
21 CFR 522.2476.
The regulation authorizes specified trenbolone acetate ear implants for steers and heifers, with feed-efficiency and weight-gain indications. It is not a human authorization.
Read the original sourceWHO · historical human observations
Official toxicology review of historical study
WHO/JECFA, Food Additives Series 23; citing Krüskemper et al., 1967.
WHO describes a 14-day intramuscular acetate experiment in male and female volunteers. It records nitrogen retention and, at the higher exposure, menstrual disturbances in some women and reduced urinary 17-ketosteroids.
The account does not give sample size or control allocation. Nitrogen balance is not measured muscle gain, and the food-residue assessment is not a human dosing recommendation.
Read the original sourceParabolan · historical record
Archived product record
BIAM historical French product record.
The archived catalog reference identifies Parabolan as trenbolone hexahydrobenzylcarbonate, a different ester from acetate and enanthate.
Read the original sourceTrenbolone enanthate · rat muscle study
Animal experiment
American journal of physiology. Endocrinology and metabolism. PMID 21266670.
A 29-day experiment in intact and castrated male rats found increased androgen-sensitive muscle mass and partial protection against bone loss and visceral-fat accumulation. Higher exposures also increased prostate mass.
Muscle, fat, bone and prostate changes were measured in rats. No human benefit or safety estimate was measured.
Read the original sourceHuman metabolism · 1991 experiment
Single-person human metabolism study
Journal of chromatography. PMID 1874853.
One human subject received orally administered radiolabeled free trenbolone. Researchers measured urinary recovery and metabolites over 72 hours.
Oral free-parent metabolism does not establish the plasma half-life of an injected ester.
Read the original sourceHuman metabolism · 2020 experiment
Single-person human metabolism study
Frontiers in chemistry. PMID 32509736.
One healthy man received labeled trenbolone for an analytical study. Investigators collected urine and identified additional metabolites.
The experiment was designed for doping analysis, not muscle, mood, organ-safety or efficacy outcomes.
Read the original sourceTrenbolone acetate · recurrent pancreatitis case
Case report
Clinical toxicology. PMID 30101635.
A 24-year-old man had recurrent acute pancreatitis temporally associated with trenbolone-acetate use and recurrence after reuse. The authors reported an extensive workup excluding other common and uncommon causes.
Recurrence after reuse strengthens attribution within this report. A single case cannot estimate frequency or verify every product and co-exposure.
Read the original sourceUser interviews · aggression and impulsivity
Qualitative interview study
Drug and alcohol review. PMID 36992616.
Interviews involving 16 anabolic-steroid users described aggression, violent behavior and difficulty regulating impulses in connection with trenbolone.
Interviews describe experiences. They cannot establish incidence or isolate the effect of one drug.
Read the original sourceInternational interviews · benefits and adverse experiences
Qualitative interview study
Drug and alcohol review. PMID 39433468.
Thirty consumers described sought physical and psychological effects alongside emotional volatility and intrusive thoughts.
Reported benefits are not controlled efficacy findings. Participants’ harm-reduction practices were not tested for effectiveness.
Read the original source282-man survey · verbal aggression
Cross-sectional survey
The International journal on drug policy. PMID 39486244.
Among 282 men using anabolic steroids, reported trenbolone amount was associated with higher verbal-aggression scores after adjustment for age and BMI.
Self-selected participants, self-reported exposure and residual confounding prevent a causal interpretation.
Read the original sourceGlobal Drug Survey · reported health concerns
Cross-sectional survey
Drug and alcohol review. PMID 42037159.
Among 1,146 male anabolic-steroid users, the 237 reporting past-year trenbolone use reported more mood, cardiovascular and hepatic concerns than the 909 reporting other steroids without trenbolone.
The outcomes are self-reported concerns, not independently confirmed organ diagnoses. Other substances and selection can confound the comparison.
Read the original sourceClinicalTrials.gov · no exact-name trenbolone study
Trial registrations
ClinicalTrials.gov.
ClinicalTrials.gov lists no exact-name trenbolone study. Historical exposure studies and contemporary surveys remain separate human evidence.
The registry result does not establish the absence of all human research. Historical exposure studies and contemporary surveys exist.
Read the original sourceFDA · steroid-product risks
Regulatory safety review
US FDA, 2017.
Anabolic-steroid products have been associated with serious liver and cardiovascular injury, mood changes, adverse lipids, androgenic effects and reproductive suppression.
This describes class-level concerns. It does not estimate a specific compound’s risk.
Read the original sourceHuman benefit and pharmacokinetic evidence
Human clinical evidence
PubMed and ClinicalTrials.gov.
The cited evidence does not establish a modern controlled human estimate for muscle gain, strength, fat loss, visual hardness, or an exact-formulation human terminal half-life.
Why is Trenbolone in F tier?
F tier reflects the lack of controlled human benefit and safety estimates for performance use. The human reports include mood, cardiovascular and liver concerns.